INTERIM RESULTS 07 August 2025 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This document contains statements that are, or may be deemed to be, "forward-looking statements". Forward- looking statements give the Company's current expectations or forecasts of future events. These forward-looking statements may include, among other things, plans, objectives, beliefs, intentions, strategies, projections and anticipated future economic performance based on assumptions and the like that are subject t ...

Financial Performance - H1 2025 global RevPAR increased by 1.8%[15], with ADR up by 1.4%[15] and occupancy up by 0.3%pts[15] - Fee margin increased by 3.9%pts to 64.7%[15], with TTM EBITDA reaching $1.259 billion, a 10% increase[15] - Adjusted EPS increased by 19% to 242.5¢[15], and free cash flow reached $302 million[15] - The interim dividend increased by 10% to 58.6¢[15] System Growth and Development - Gross system growth increased by 7.7% YOY, and net system growth increased by 5.4% YOY[15] - A record 31.4k rooms (207 hotels) were opened in H1, a 75% increase YOY[15] - Signings reached 51.2k rooms (324 hotels), a 15% increase YOY[15] - The pipeline consists of 338k rooms (2,276 hotels), representing 34% of the current system size[16] Capital Returns - $423 million (47%) of the $900 million share buyback program has been returned, representing 2.4% of the opening share count[15] - The company expects to return >$1.1 billion in 2025, representing 5.9% of the opening market cap[15] Strategic Priorities - Loyalty enrolments increased by 22% YOY in H1[102], with ~65% of room nights booked by members[102] - Co-brand fee revenue is on track to double by 2025 and more than triple by 2028[114] Regional Performance - Americas RevPAR increased by 1.4%[184], with a fee margin of 82.7%[184] - EMEAA RevPAR increased by 4.1%[188], with a fee margin of 65.8%[188] - Greater China RevPAR decreased by 3.2%[192], with a fee margin of 57.9%[192]

Financial Performance - Total Revenues for the fiscal year 2024.4-2025.3 reached 2,874,821 million yen[5], a slight increase from 2,814,361 million yen in the previous fiscal year[5] - Net Income Attributable to ORIX Corporation Shareholders for the fiscal year 2024.4-2025.3 was 351,630 million yen[5], compared to 346,132 million yen in the previous fiscal year[5] - Return on Equity (ROE) for the quarter 2025.4-6 increased to 10.4%[5] from 9.2% in the same quarter of the previous year[5] - Return on Assets (ROA) for the quarter 2025.4-6 increased to 2.53%[5] from 2.19% in the same quarter of the previous year[5] Segment Performance - Total segment profits reached 544,668 million yen[7], with an adjustment of -64,205 million yen[7] leading to an income before income taxes of 480,463 million yen[7] - Corporate Financial Services and Maintenance Leasing reported segment profits of 90,329 million yen[7] and segment assets of 1,884,565 million yen[7] - Real Estate segment profits were 70,541 million yen[7] with segment assets of 1,158,293 million yen[7], showing a segment asset ROA of 4.26%[7] - PE Investment and Concession segment profits amounted to 98,872 million yen[7] with segment assets of 1,022,944 million yen[7], resulting in a segment asset ROA of 6.96%[7] - Insurance segment profits were 74,399 million yen[7] with segment assets of 3,009,234 million yen[7], and a segment asset ROA of 1.80%[7] Asset and Funding - Total Assets reached 16,866,251 million yen[5], with Total Liabilities at 12,691,036 million yen[5] and Total ORIX Corporation Shareholders' Equity at 4,089,782 million yen[5] - The Shareholders' Equity Ratio stood at 24.2%[6], and the Debt-to-Equity Ratio was 2.1 times[6] - The company maintains strong liquidity, with a liquidity coverage ratio of 2,086%[86]

Financial Performance - Q1 FY2025 Results (Continuing Operations) - Sales increased by 563 billion yen (+2%) year-on-year to 26216 billion yen, with an approximately 8% increase on a constant currency basis[6, 8] - Operating income increased by 908 billion yen (+36%) year-on-year to 3400 billion yen, with operating income margin at 130%, a 33 percentage point increase[6] - Net income attributable to Sony Group Corporation's stockholders increased by 489 billion yen (+23%) to 2590 billion yen[6] Segment Performance - Q1 FY2025 - Game & Network Services (G&NS) sales increased by 716 billion yen (+8%) to 9365 billion yen, and operating income increased by 827 billion yen (+127%) to 1480 billion yen[9, 22] - Music sales increased by 233 billion yen (+5%) to 4653 billion yen, and operating income increased by 69 billion yen (+8%) to 928 billion yen[9, 26] - Pictures sales decreased by 102 billion yen (-3%) to 3271 billion yen, but operating income increased by 74 billion yen (+65%) [9, 30] - Entertainment, Technology & Services (ET&S) sales decreased by 667 billion yen (-11%) to 5343 billion yen, and operating income decreased by 209 billion yen (-33%) to 431 billion yen[9, 39] - Imaging & Sensing Solutions (I&SS) sales increased by 547 billion yen (+15%) to 4082 billion yen, and operating income increased by 176 billion yen (+48%) to 543 billion yen[9, 44, 47] FY2025 Forecast (Continuing Operations) - Sales forecast remains unchanged at 117 trillion yen[10, 16] - Operating income forecast increased by 50 billion yen (+4%) to 133 trillion yen after considering a 70 billion yen estimated tariff impact[10, 11, 16] - Net income attributable to Sony Group Corporation's stockholders forecast increased by 40 billion yen (+4%) to 970 billion yen[10, 15] Spin-off of Financial Services Business - Sony plans to execute a partial spin-off of Sony Financial Group Inc (SFGI) in October 2025, classifying the Financial Services business as a discontinued operation from Q1 FY25[3, 4] - A considerable one-time loss will be recorded in the consolidated statements of income at the time of the execution of the Spin-off, but there will be no impact on operating income and net income from continuing operations[52]

FY2026 Forecast Revision - Toyota revised its FY2026 operating income forecast downward by 06 trillion yen, from 38 trillion yen to 32 trillion yen [5] - The impact of US tariffs is estimated to be 14 trillion yen, a downward revision from the previous forecast of 12 trillion yen [5] - Consolidated vehicle sales forecasts remain unchanged at 98 million units [35] FY2026 First Quarter Performance - Operating income for the first quarter of FY2026 was 11661 billion yen, a decrease of 1423 billion yen year-on-year [15] - Net income attributable to Toyota Motor Corporation decreased by 4920 billion yen to 8413 billion yen [15] - Total retail vehicle sales increased by 73% year-on-year, reaching 2829 thousand units [11] Sales Performance - Toyota and Lexus vehicle sales increased by 61% year-on-year, reaching 2643 thousand units [11] - Electrified vehicle sales increased by 171% year-on-year, reaching 1259 thousand units, representing 476% of total retail vehicle sales [11] - Consolidated vehicle sales increased by 71% year-on-year to 2411 thousand units [13] Financial Analysis - Sales revenues increased by 4154 billion yen to 122533 billion yen [15] - The operating income margin decreased from 111% to 95% [15] - The analysis of consolidated operating income indicates a negative impact of 4500 billion yen due to tariffs [19] Regional Performance - In North America, vehicle sales increased by 142% [22] - In Asia, vehicle sales increased by 127% [22] - China Business operating income of consolidated subsidiaries increased by 104 billion yen [27] Financial Forecasts - Sales Revenues are forecasted to be 485 trillion yen [38] - Net Income Attributable to Toyota Motor Corporation is forecasted to be 266 trillion yen [38]

ATA Creativity Global NASDAQ: AACG 2025 SECOND QUARTER EARNINGS CALL August 6, 2025 Speakers: Ruobai Sima, CFO Jun Zhang, President P A G E 1 Safe Harbor Statement This presentation was developed by ATA Creativity Global ("ACG" or the "Company") and is intended to be used solely in connection with ACG's earnings call for the second quarter ("Q2 2025") and six months ("H1 2025") ended June 30, 2025. This presentation is not to be construed as an offer to sell or the solicitation of an offer to buy the Compan ...

1H 25 Results For personal use only Alexis George, CEO Blair Vernon, CFO 7 August 2025 1 1H 25 overview 2H 25 priorities 7 1H 25 overview Alexis George, CEO For personal use only 3 Business unit performance 5 Capital For personal use only 2 1H 25 Financial results Costs 6 FY 25 guidance 4 1H 25 highlights Group underlying NPAT +9.2% to $131m Controllable costs improved 4.4% to $303m 1H 25 interim dividend 2cps 20% franked Delivering on strategic priorities building on momentum in cashflows in wealth busines ...

Financial Performance & Growth - The company reported a 39% profit growth [30] - Underlying EBITDA for 1H26 is projected to be $14 million to $16 million [30, 56] - Underlying EBITDA increased by 20% to $23.5 million from $19.5 million [43] - Underlying EBITDAR Per Care Bed increased by 13% to $27.9K from $24.7K [45] - Total FY25 cash dividend was 1.45cps, compared to 0.70cps in FY24 [45] Expansion & Acquisitions - Acquired St Allisa, a 109-bed care home, through a leaseback arrangement [24, 27, 30] - Acquired 51% of Cibus Catering Limited, resulting in a $4.1 million revenue uplift [30] - Pursuing capital-light expansion focused on new-build 100-bed care homes leased from private investors [28] Operational Efficiency & Staffing - Company-wide staff turnover decreased by 30% year-on-year, reaching a record low [48] - 86% of care homes audited in FY25 received 4-Year Certification [49] - Average occupancy is trending upwards, reaching approximately 95% [50] - The company acquired 920,000 shares for $280,000, with an average buyback price of 30.4cps [39, 40]

Approved for release by the Board of Directors For personal use only Executive Summary EOS continues to commercialise IP with this A$125m contract. Laser weapon technology is a significant growth opportunity for EOS Drone warfare is driving an urgent market need Directed energy weapons are a critical defence layer High Energy Laser Weapon Investor Update Webinar – 7 August 2025 Dr. Andreas Schwer, Managing Director & Chief Executive Officer Clive Cuthell, Chief Financial Officer & Chief Operating Officer EO ...

Dimerix Overview - Dimerix is developing DMX-200, a lead drug candidate in Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS)[14] - FSGS is a rare kidney disease with no approved treatments, leading to irreversible kidney damage, dialysis, transplant, or death[14] - Dimerix has secured orphan drug designation for DMX-200, providing regulatory, marketing exclusivity, and pricing benefits in key territories[14] - Dimerix has licensing partners across key territories for DMX-200[14] Financial Achievements and Partnerships - Dimerix has received over AU$65 million in total payments to date[14,54] - Licensing deals are collectively valued up to approximately AU$1.4 billion in total upfront and potential milestone fees plus royalties[14,53] - A 3rd development and license agreement for DMX-200 in Japan is valued up to ¥10.5 billion (~AU$107 million) in upfront/milestones, plus royalties[17] - A 4th license agreement for DMX-200 in the United States is valued up to US$590 million (~AU$940 million) in upfront/milestones, plus royalties[17] Clinical Trial and Regulatory Progress - The FDA confirmed proteinuria as an acceptable endpoint for full marketing approval in the US[17] - The ACTION3 study has enrolled 225 patients, with 52 patients enrolled in the Open Label Extension Study as of August 5, 2025[33] - The Phase 3 trial aims to recruit a total of approximately 286 patients[33] - Dimerix held a positive Type C meeting with the FDA in March 2025 regarding proteinuria trial endpoints for full approval and potential accelerated approval for DMX-200[41] Market Opportunity - The estimated global incidence of FSGS is over 200,000 per year[61] - The estimated incidence of FSGS per year across all Dimerix licensed territories is approximately 50,071[61]